10-Q: Zomedica Corp. Reports Q3 2024 Results, Revenue Up 10% Year-Over-Year but Faces Significant Impairment Charges

Zomedica Corp. saw a 10% increase in revenue year-over-year for Q3 2024, but reported a significant net loss due to impairment charges.

Summary

• Zomedica Corp. reported a net revenue of $6.997 million for the three months ended September 30, 2024, a 10% increase compared to $6.347 million in the same period of 2023.
• The company's net loss for the quarter was $6.697 million, a significant increase from the $491,000 loss in Q3 2023.
• For the nine months ended September 30, 2024, net revenue reached $19.390 million, a 9% increase from $17.849 million in the same period of 2023.
• The net loss for the first nine months of 2024 was $39.788 million, compared to a net loss of $12.123 million in the same period of 2023.
• The company experienced a significant impairment expense of $16.024 million during the nine months ended September 30, 2024, impacting profitability.
• The increase in revenue was primarily driven by growth in both consumables and capital sales in the PulseVet and TRUFORMA product lines.
• General and administrative expenses increased by 11% for the quarter and 17% for the nine-month period, driven by professional fees and amortization expenses.
• Research and development expenses saw a substantial increase of 113% for the quarter and 94% for the nine-month period, due to the development of new diagnostic products.
• Selling and marketing expenses also increased by 17% for the quarter and 21% for the nine-month period, due to increased hiring and marketing campaigns.
• The company's cash and cash equivalents decreased to $9.747 million as of September 30, 2024, from $12.952 million at the end of 2023.

Sentiment

Score: 4

Explanation: The document presents mixed results. While revenue growth is positive, the significant net loss and impairment charges raise concerns about the company's financial health and future prospects. The sentiment is cautiously negative.

Positives

• The company experienced a 10% increase in revenue for the three months ended September 30, 2024, compared to the same period in 2023.
• Gross profit margin improved to 72% for the three months ended September 30, 2024, compared to 69% for the same period in 2023.
• The company has remediated a previously identified material weakness in internal controls over financial reporting as of June 30, 2024.

Negatives

• The company reported a significant net loss of $6.697 million for the three months ended September 30, 2024.
• The company recorded a substantial impairment expense of $16.024 million during the nine months ended September 30, 2024.
• Cash and cash equivalents decreased to $9.747 million as of September 30, 2024, from $12.952 million at the end of 2023.

Risks

• The company's future profitability is uncertain, as it expects to continue recording net losses until revenue sufficiently offsets operating expenses.
• The company's reliance on estimates and assumptions, particularly in areas like intangible assets, impairment testing, and revenue recognition, could lead to material differences in actual results.
• The company's long-term cash requirements are subject to various factors, including the costs of development, commercialization, and potential acquisitions.
• The company is exposed to risks related to climate change, which could impact operations and increase costs.
• The company's ability to maintain the listing of its common shares on the NYSE American exchange is a risk factor.

Future Outlook

The company expects revenue to increase in subsequent periods as it increases its sales, marketing, and commercialization efforts. The company also anticipates that cost of revenue will continue to increase in future periods in line with the expected growth in unit sales. The company expects to continue recording net losses in future periods until it has sufficient revenue from product sales to offset its operating expenses.

Management Comments

• Management believes that existing cash is sufficient to fund expected short-term needs.
• Management believes that existing cash resources will be sufficient to fund expected operational requirements for the foreseeable future.
• Management regularly evaluates business plans and strategy, which may result in changes to cash requirements.

Industry Context

The veterinary health industry is experiencing growth, and Zomedica is positioning itself to capitalize on this trend with its diagnostic and therapeutic products. The company's focus on unmet needs of clinical veterinarians aligns with the industry's demand for innovative solutions. However, the company faces competition from established players and must continue to innovate and expand its market presence to achieve long-term success.

Comparison to Industry Standards

• Zomedica's revenue growth of 10% year-over-year in Q3 2024 is a positive sign, but it needs to be compared to the growth rates of its competitors in the veterinary health industry, such as IDEXX Laboratories and Zoetis, to assess its relative performance.
• The significant impairment charge of $16.024 million indicates potential issues with the valuation of acquired assets, which is a common challenge in the industry, especially for companies that have grown through acquisitions. This needs to be compared to the impairment charges of other companies in the sector.
• Zomedica's gross profit margin of 72% in Q3 2024 is a positive indicator, but it needs to be compared to the gross profit margins of its competitors to assess its efficiency in managing costs.
• The increase in research and development expenses by 113% in Q3 2024 shows the company's commitment to innovation, but it needs to be compared to the R&D spending of its competitors to assess its relative investment in future growth.
• The decrease in cash and cash equivalents to $9.747 million as of September 30, 2024, is a concern, and the company needs to manage its cash flow effectively to ensure it has sufficient resources to fund its operations and growth plans. This needs to be compared to the cash positions of its competitors.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders will be concerned about the significant net loss and impairment charges.
• Employees may be affected by the company's financial performance and any potential restructuring.
• Customers may be impacted by the company's ability to continue to provide products and services.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to focus on increasing sales, marketing, and commercialization efforts.
• The company will continue to develop new diagnostic products.
• The company will continue to evaluate its business plans and strategy.

Key Dates

Keywords

Zomedica, financial results, Q3 2024, revenue, net loss, impairment, veterinary health, diagnostics, therapeutics, stock appreciation rights